Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03109262 · ClinicalTrials.gov registry record · NA
Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 42
- Enrollment target
NCT03109262: Completed NA study, sponsored by Stanford University.
NCT03109262 is a NA study that has completed, run by Stanford University. The registered enrollment target is 42 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03109262, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 42 participants
- Enrollment target
Study Summary
This clinical trial studies how well yttrium-90 (Y90) glass microspheres positron emission tomography (PET)/computed tomography (CT) works in imaging patients with liver tumors . Images produced by PET/CT may provide better information about the distribution of particles, such as Y90 glass microspheres, delivered for selective internal radiation therapy (SIRT) as compared to regular medical care images useing technetium Tc-99m albumin-aggregated single photon emission computed tomography (SPECT)/CT images.
Primary Outcome
Image quality for 90Y PET/CT scan images was assessed relative to the expected image quality of Standard of Care (SoC) 99mTc-MAA SPECT/CT scans obtained from the same participant. Assessments were conducted at 5, 10, 15 and 20 minutes after infusion. Scans were assessed on a 1 to 5 Likert scale by 2 Nuclear Medicine physicians who were blinded to patient information. The Likert scale for image quality was established as follows: 1. = Non-diagnostic 2. = Suboptimal 3. = Acceptable 4. = Good 5. =
Interventions
- PROCEDURE Computed Tomography (CT)
- PROCEDURE Positron Emission Tomography (PET)
- DEVICE 90-Yttrium (Y-90) Glass Microspheres
- DIAGNOSTIC_TEST Technetium 99mTc albumin aggregated (99mTc-MAA)
- PROCEDURE Single-photon emission computerized tomography (SPECT) scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2017-02-15 |
| Est. Completion | 2021-02-28 |
| Phase | NA |
What the finished NCT03109262 record still lists
NCT03109262 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 5 interventions - of which Computed Tomography (CT) is the first listed.
NCT03109262 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03109262 about?
NCT03109262 is a clinical study titled "Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors". This clinical trial studies how well yttrium-90 (Y90) glass microspheres positron emission tomography (PET)/computed tomography (CT) works in imaging patients with liver tumors . Images produced by PET/CT may provide better information about the distribution of particles, such as Y90 glass microsphe...
What is the current status of trial NCT03109262?
This trial is currently completed. It is a NA study. The enrollment target is 42 participants. The study started on 2017-02-15. Estimated completion is 2021-02-28.
What interventions are being tested in trial NCT03109262?
The interventions under investigation include: Computed Tomography (CT) (PROCEDURE), Positron Emission Tomography (PET) (PROCEDURE), 90-Yttrium (Y-90) Glass Microspheres (DEVICE), Technetium 99mTc albumin aggregated (99mTc-MAA) (DIAGNOSTIC_TEST), Single-photon emission computerized tomography (SPECT) scan (PROCEDURE).
Who is sponsoring clinical trial NCT03109262?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03109262's enrollment target sits among peer trials
42 1436th of 2000 higher than 555 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI